Vaxart Inc. Stock
Vaxart Inc. Stock
Vaxart Inc. dominated the market today, gaining €0.060 (10.000%).
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | 10.000% | 120.588% | 114.286% | -20.000% | 114.286% | -46.352% | -88.889% |
| aTyr Pharma Inc | -3.850% | -5.455% | -6.306% | -85.556% | -13.333% | -74.447% | -84.242% |
| Larimar Therapeutics Inc. | -2.160% | -2.113% | -18.235% | -20.571% | -16.265% | -31.863% | -82.270% |
| Inotiv Inc. | 2.130% | 5.381% | -21.667% | -88.810% | 9.813% | -93.237% | -95.648% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
